Literature DB >> 30786745

Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study.

Pankaj Arora1,2, Rajat Kalra3, Peter W Callas4, Kristine S Alexander5, Neil A Zakai5,6, Virginia Wadley7, Garima Arora1, Brett M Kissela8, Suzanne E Judd9, Mary Cushman5,6.   

Abstract

Objective- Increased Lp(a) [lipoprotein(a)] is associated with coronary heart disease risk, but links with stroke are less consistent. Blacks have higher Lp(a) levels and stroke incidence than whites but have been underrepresented in studies. We hypothesized that Lp(a) is a risk factor for ischemic stroke and that risk differs by race. Approach and Results- REGARDS (Reasons for Geographic and Racial Differences in Stroke) recruited 30 239 black and white US adults aged ≥45 in 2003-2007 to study regional and racial differences in stroke mortality. We measured baseline Lp(a) by immunonephelometric assay in 572 cases of incident ischemic stroke and a 967-person cohort random sample. The hazard ratio of stroke by baseline Lp(a) was calculated using Cox proportional hazards models, stratified by race. Lp(a) was modeled in sex- and race-specific quartiles, given known differences in distributions by race and sex. Interactions were tested by including interaction terms in the proportional hazards models, with P<0.10 considered statistically significant. After adjustment for age, sex, and stroke risk factors, being in the fourth versus the first Lp(a) quartile was weakly associated with ischemic stroke overall, hazard ratio, 1.45 (95% CI, 0.96-2.19). In blacks, the hazard ratio was 1.96 (95% CI, 1.10-3.46), whereas in whites HR was 1.14 (95% CI, 0.64-2.04); P interaction=0.12. Lp(a) was lower in men than women, but associations with stroke in men and women were similar. Conclusions- We confirm that Lp(a) is a risk factor for ischemic stroke. Further research is needed to confirm the role of racial differences of the Lp(a) risk multiplier in ischemic stroke.

Entities:  

Keywords:  incidence; lipoprotein(a); proportional hazards models; risk factors; stroke

Mesh:

Substances:

Year:  2019        PMID: 30786745      PMCID: PMC6511401          DOI: 10.1161/ATVBAHA.118.311857

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  35 in total

Review 1.  Lipoprotein(a): more interesting than ever after 50 years.

Authors:  Joseph B Dubé; Michael B Boffa; Robert A Hegele; Marlys L Koschinsky
Journal:  Curr Opin Lipidol       Date:  2012-04       Impact factor: 4.776

2.  Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women.

Authors:  T T Nguyen; R D Ellefson; D O Hodge; K R Bailey; T E Kottke; H S Abu-Lebdeh
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

3.  American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors.

Authors:  R L Sacco; E J Benjamin; J P Broderick; M Dyken; J D Easton; W M Feinberg; L B Goldstein; P B Gorelick; G Howard; S J Kittner; T A Manolio; J P Whisnant; P A Wolf
Journal:  Stroke       Date:  1997-07       Impact factor: 7.914

Review 4.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.

Authors:  Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2017-02-14       Impact factor: 24.094

Review 5.  Gender and racial disparities in adherence to statin therapy: a meta-analysis.

Authors:  Jennifer Lewey; William H Shrank; Ashna D K Bowry; Elaine Kilabuk; Troyen A Brennan; Niteesh K Choudhry
Journal:  Am Heart J       Date:  2013-03-26       Impact factor: 4.749

6.  Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Salim S Virani; Ariel Brautbar; Brian C Davis; Vijay Nambi; Ron C Hoogeveen; A Richey Sharrett; Josef Coresh; Thomas H Mosley; Joel D Morrisett; Diane J Catellier; Aaron R Folsom; Eric Boerwinkle; Christie M Ballantyne
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

7.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

Review 8.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

Review 9.  Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.

Authors:  Mark J Graham; Nick Viney; Rosanne M Crooke; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2015-11-04       Impact factor: 5.922

Review 10.  Lipoprotein(a), cardiovascular disease, and contemporary management.

Authors:  Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2013-11       Impact factor: 7.616

View more
  17 in total

1.  PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults.

Authors:  Matthew T Mefford; Santica M Marcovina; Vera Bittner; Mary Cushman; Todd M Brown; Michael E Farkouh; Sotirios Tsimikas; Keri L Monda; J Antonio G López; Paul Muntner; Robert S Rosenson
Journal:  J Lipid Res       Date:  2019-09-11       Impact factor: 5.922

2.  Biomarkers as MEDiators of racial disparities in risk factors (BioMedioR): Rationale, study design, and statistical considerations.

Authors:  D Leann Long; Boyi Guo; Leslie A McClure; Byron C Jaeger; Stephanie E Tison; George Howard; Suzanne E Judd; Virginia J Howard; Timothy B Plante; Neil A Zakai; Insu Koh; Katharine L Cheung; Mary Cushman
Journal:  Ann Epidemiol       Date:  2021-11-03       Impact factor: 3.797

3.  Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease.

Authors:  Lisandro D Colantonio; Vera Bittner; Monika M Safford; Santica Marcovina; Todd M Brown; Elizabeth A Jackson; Mei Li; J Antonio G López; Keri L Monda; Timothy B Plante; Shia T Kent; Paul Muntner; Robert S Rosenson
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

4.  Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort.

Authors:  Eric J Brandt; Arya Mani; Erica S Spatz; Nihar R Desai; Khurram Nasir
Journal:  J Clin Lipidol       Date:  2020-07-03       Impact factor: 4.766

Review 5.  Identifying Genetic and Biological Determinants of Race-Ethnic Disparities in Stroke in the United States.

Authors:  Debora Kamin Mukaz; Neil A Zakai; Salvador Cruz-Flores; Louise D McCullough; Mary Cushman
Journal:  Stroke       Date:  2020-10-26       Impact factor: 7.914

6.  Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors.

Authors:  Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet
Journal:  Metabolism       Date:  2021-01-07       Impact factor: 8.694

7.  Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a).

Authors:  Santica M Marcovina; Noémie Clouet-Foraison; Marlys L Koschinsky; Mark S Lowenthal; Allen Orquillas; Michael B Boffa; Andrew N Hoofnagle; Tomáš Vaisar
Journal:  Clin Chem       Date:  2021-03-01       Impact factor: 12.167

8.  C-reactive protein and stroke risk in blacks and whites: The REasons for Geographic And Racial Differences in Stroke cohort.

Authors:  Christina R Evans; D Leann Long; George Howard; Leslie A McClure; Neil A Zakai; Nancy S Jenny; Brett M Kissela; Monika M Safford; Virginia J Howard; Mary Cushman
Journal:  Am Heart J       Date:  2019-08-12       Impact factor: 4.749

9.  Association of Lipoprotein (a) variants with risk of cardiovascular disease: a Mendelian randomization study.

Authors:  Juan Xia; Chunyue Guo; Kuo Liu; Yunyi Xie; Han Cao; Wenjuan Peng; Yanyan Sun; Xiaohui Liu; Bingxiao Li; Ling Zhang
Journal:  Lipids Health Dis       Date:  2021-06-01       Impact factor: 3.876

10.  Serum lipoprotein(a) and risk of hemorrhagic stroke among incident peritoneal dialysis patients: a large study from a single center in China.

Authors:  Yanbing Chen; Xiaojiang Zhan; Qing Zhao; Xin Wei; Jun Xiao; Caixia Yan; Wei Zhang
Journal:  Ren Fail       Date:  2019-11       Impact factor: 2.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.